|Articles|October 16, 2019
Treatment of Plaque Psoriasis
On August 1 2019, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. The decision is supported, in part, by the Enstilar Pediatric Study (NCT02387853) in adolescents age 12 to 17 with psoriasis of the body and scalp.
Related Content
Latest CME
Trending on Dermatology Times
1
KT-621 in Atopic Dermatitis: What Early EASI and Pruritus Data Show
2
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
3
Dermatology Times Spot Test: June 14, 2026
4
Social Media Mythbusters: Skin Cycling
5